Cryoglobulinemia is a disorder caused by the hepatitis C virus. The symptoms and health problems of cryoglobulinemia lead to mild to moderate to severe disease and for some people, it can be life-threatening. Treating cryoglobulinemia with direct-acting antiviral medications has been shown to reduce the symptoms of the disease and for some, it can lead to a remission and cure of cryoglobulinemia.
This objective of this clinical trial is to treat and cure hepatitis C genotype 1 and measure the effect of curing or reducing the complications of hepatitis C-related cryoglobulinemia.
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
To view the entire clinical trial information, click here